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Cu isotopic signature in blood 
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Sara Lauwens1, Marta Costas-Rodríguez1, Hans Van Vlierberghe2 & Frank Vanhaecke1
End-stage liver disease (ESLD) is life-threatening and liver transplantation (LTx) is the definitive 
treatment with good outcomes. Given the essential role of hepatocytes in Cu homeostasis, the 
potential of the serum Cu isotopic composition for monitoring a patient’s condition post-LTx was 
evaluated. For this purpose, high-precision Cu isotopic analysis of blood serum of ESLD patients pre- 
and post-LTx was accomplished via multi-collector ICP-mass spectrometry (MC-ICP-MS). The Cu isotopic 
composition of the ESLD patients was fractionated in favour of the lighter isotope (by about −0.50‰). 
Post-LTx, a generalized normalization of the Cu isotopic composition was observed for the patients with 
normal liver function, while it remained light when this condition was not reached. A strong decrease 
in the δ65Cu value a longer term post-LTx seems to indicate the recurrence of liver failure or cancer. 
The observed trend in favour of the heavier Cu isotopic composition post-LTx seems to be related with 
the restored biosynthetic capacity of the liver, the restored hepatic metabolism and/or the restored 
biliary secretion pathways. Thus, Cu isotopic analysis could be a valuable tool for the follow-up of liver 
transplant patients and for establishing the potential recurrence of liver failure.
Copper is an essential trace element required as cofactor in many enzymes. However, when it is present in excess, 
the high oxidative potential of free Cu ions can generate reactive free radicals with subsequent cellular damage. 
Thus, Cu homeostasis needs to be regulated strongly to maintain cellular Cu concentrations at levels at which 
both toxicity and deficiency are avoided1–3.
The liver, as the principal storage site for Cu, plays a key role in Cu homeostasis. Dietary copper is absorbed 
in the intestine and transported to the liver via the portal blood, where it is taken up by hepatocytes. The cop-
per taken up by the hepatocytes is incorporated into the copper-dependent ferroxidase ceruloplasmin (Cp) and 
subsequently secreted in the blood for distribution throughout the body. Total body Cu levels are controlled by 
excretion of excess Cu via the bile1,4,5.
Cu status in the body is altered in liver disease, especially when there are obstructions in bile flow and/or 
impaired protein synthesis6,7. Studies with radioactive Cu have shown that Cu turnover in the liver increases 
from 20–30 days in healthy individuals to 600–700 days for patients with biliary cirrhosis8. Hepatic Cu overload 
has been observed in liver diseases that arise from etiologies such as Wilson’s disease (WD)9, viral hepatitis10, 
cholestasis9 and excessive alcohol consumption11. WD is a genetic disorder that leads to Cu accumulation, first in 
the liver, but ultimately also in the brain and other tissues12, and to low or normal serum Cu concentrations com-
pared to controls. In contrast, high or normal Cu concentrations in blood serum can be observed in cirrhosis13 
and hepatocellular carcinoma (HCC) patients. End-stage liver disease (ESLD) can arise from these etiologies and 
can be complicated by other life-threatening complications (e.g., hepatic encephalopathy, ascites, portal hyper-
tension and hepatorenal syndrome)14,15. An elevated risk of HCC and extra-hepatic cancers has been established 
in patients with cirrhosis16.
As a result of the above, Cu levels in serum of ESLD patients frequently overlap with those of the reference 
population and there is no clear relation between the Cu concentration and the clinical course of the disease. 
Recently however, the potential of the Cu isotopic composition in blood serum as a diagnostic tool for diseases 
affecting Cu metabolism has been suggested17. Patients with Wilson’s disease18, ESLD19 and HCC20 showed a 
lighter serum Cu isotopic composition than did the reference population.
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Due to the complexity of the liver, there is no single clinical test for assessing hepatic disorders21,22. A series of 
tests, for the determination of what is frequently termed “liver function parameters”, is performed for the manage-
ment of liver diseases. These parameters are used for i) detection of hepatic injury, e.g., aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT), ii) assessment of hepatic biosynthetic capacity, e.g., albumin (Alb), 
prothrombin time (PT) and international normalized ratio (INR), and iii) assessment of hepatic metabolism, e.g., 
bilirubin (Bili)22. Liver transplantation (LTx) is the definitive treatment with successful outcomes for patients with 
ESLD, for patients with HCC development and for patients with acute liver failure (ALF)23. In this context, the 
time on the liver transplant waiting list, the transplant itself and the recovery period are crucial factors determin-
ing the outcome of LTx.
The aim of this research was to investigate the Cu isotopic signature in blood serum of patients with ESLD 
pre-LTx and its evolution post-LTx to evaluate the capability of this parameter for following up the patients and 
for establishing the potential recurrence of liver failure. For this, high-precision Cu isotopic analysis of ~100 
blood serum samples from 32 liver transplant patients was carried out via multi-collector ICP-mass spectrometry 
(MC-ICP-MS), after digestion of the serum and chromatographic isolation of the target element. For each patient, 
blood serum samples collected pre- and post-LTx were analyzed. In addition, serum samples collected at several 
time points post-LTx (up to > 1 year post-LTx for some patients) were included.
Results
The study group consisted of 32 patients with ESLD, who underwent LTx between September 2011 and April 
2015. The patients were subjected to LTx because of different diseases, e.g., cirrhosis, steatosis, cholestasis, hepa-
titis, hypertension, amyloidosis, polycystic liver and HCC (Table 1). Information on the patient´s diagnosis, liver 
function parameters pre-LTx and post-LTx (including bilirubin, AST, ALT, PT, INR and Alb), post-LTx compli-
cations and other chronic diseases, is given in the Supplementary Table S1.
The Cu isotopic composition, expressed as δ 65Cu (± 2 s.d.) value, and the Cu concentration in blood serum of 
the ESLD patients pre- and post-LTx are provided in the Supplementary Table S2. The δ -notation indicates the 
relative difference (in ‰) between the Cu isotope ratio (65Cu/63Cu) in the sample and that of the NIST SRM 976 
Cu isotopic reference material.
Patients with ESLD (N = 32) showed an average serum Cu level of 750 ± 770 (2 s.d.) μ g L−1 pre-LTx and 
810 ± 580 (2 s.d.) μ g L−1 three months post-LTx. No significant differences were observed in Cu serum concen-
trations between the two cohorts (related samples Wilcoxon signed rank test, p > 0.05) (Fig. 1a). However, the Cu 
isotopic composition in serum of these ESLD patients pre-LTx was fractionated in favour of the light Cu isotope. 
The same trend was observed in patients who developed HCC20, but no significant difference was observed in δ 
65Cu value between the ESLD cohort pre-LTx with HCC (N = 10) and that without HCC (N = 22) (related sam-
ples Wilcoxon signed rank test, p > 0.05). The average δ 65Cu value was − 0.80 ± 0.57 (2 s.d.)‰ (N = 32), while the 
reference range reported for assumed healthy individuals is − 0.26 ± 0.40 (2 s.d.)‰ (N = 47)24. These results were 
in agreement with the average δ 65Cu value reported in our previous work on liver cirrhosis patients (− 0.78 ± 0.72 
(2 s.d.)‰, N = 25)19. Three months post-LTx, the average δ 65Cu value had significantly (related samples Wilcoxon 
signed rank test, p = 0.007) risen to − 0.63 ± 0.55 (2 s.d.)‰ (N = 32) (Fig. 1b).
In Fig. 2a, the serum δ 65Cu values obtained for each patient pre-LTx, 3 months post-LTx and – for some 
patients – 9 months post-LTx are shown. As can be seen, the serum Cu isotopic composition tends to higher val-
ues for most of the patients, i.e. the δ 65Cu value normalizes post-LTx when the patient recovers normal liver con-
dition, in concordance with the recovery of the “liver function parameters” (Table 2 and Supplementary Table S1). 
About 40% of the patient cohort studied (N = 32) reached the reference range 3 months post-LTx, increasing to 
∼ 60% 9 months post-LTx. In Fig. 2b, the serum Δ δ 65Cu (‰) values, defined as Δ δ 65Cu = δ 65Cupost-LTx − δ 
65Cupre-LTx, obtained 3 months and – for some patients – 9 months post-LTx are shown. A mean and maximum Δ 
δ 65Cu (‰) value of respectively 0.16 and 1.01 was observed 3 months post-LTx.
Disease Number of patients
Ethylic C 11 (2 of which with HCC)
HCV induced C 5 (3 of which with HCC)
PSC 5
ISC 1
C (not specified) 2 (1 of which with HCC)
NASH 2 (2 of which with HCC)
HBV 2 (1 of which with HCC and 1 with HCC and PBC)
ALF 1
Polycystic liver 1
Familial amyloidosis 1
Non-cirrhotic portal hypertension 1
Total ESLD cohort 32 (10 of which with HCC)
Table 1.  Description of the patients’ etiology. C = cirrhosis, HCV = hepatitis C virus, PSC = primary 
sclerosing cholangitis, ISC = incomplete septal cirrhosis, NASH = non-alcoholic steato-hepatitis, 
HBV = hepatitis B virus, PBC = primary biliary cirrhosis.
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To assess the variations in the Cu isotopic composition further in time post-LTx, the follow-up was extended 
for twelve patients to ≥ 9 months post-LTx (Figs 3 and 4). Patients 5, 9, 12, 17, 20, 22, 24 (Fig. 3) and 23 (Fig. 4) 
showed a gradual enrichment in δ 65Cu as a function of time, whether or not accompanied with some fluctuations.
Patient 23 (Fig. 4a), diagnosed with polycystic liver disease, showed a normal pre-transplant liver function 
but post-LTx, a temporary dysfunction of the new liver was established. This is likely the reason for the slight 
decline of δ 65Cu ± 2 s.d. (‰) from − 0.58 ± 0.13 (pre-LTx) to − 0.84 ± 0.04 (3 months post-LTx). After 3 months, 
δ 65Cu increases towards the range of healthy individuals with a δ 65Cu value of − 0.27 ± 0.15 (2 s.d.)‰. The same 
behaviour was observed for patient 32 (Fig. 4c), suffering from familial amyloidosis, a disease characterized by 
Figure 1. Boxplots of serum Cu concentrations and isotopic composition of liver transplant patients 
pre-LTx and 3 months post-LTx. Empty circles are outliers. (a) Serum copper concentrations (μ g L−1). No 
significant change in serum Cu levels post-LTx (p > 0.05). (b) Copper isotopic compositions in serum. A 
significant enrichment in 65Cu was observed post-LTx (p = 0.007).
Figure 2. δ65Cu and Δδ65Cu values in serum samples of pre- and post-LTx (3 and 9 months) patients.  
(a) δ 65Cu values. Error bars represent 2 s.d. The full line represents the average value for healthy individuals as 
reported by Albarède et al.24. The dotted lines represent ± 1 s.d. on this average. For patient 11, a serum sample 
3 months post-LTX was not available and a sample collected 6 months post-LTx was included instead. For 
patients 7 and 28, serum samples 9 months post-LTx were not available and samples collected 5 months post-
LTx were analysed instead. The low δ 65Cu values observed in the ESLD population tend to increase post-LTx. 
(b) Δ δ 65Cu values.
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extracellular deposition of amyloid in various organs, leading to multisystem organ dysfunction25. This patient 
showed a normal pre-LTx liver function, but post-LTx, some abnormalities were evident from the liver func-
tion parameters. This possibly explains the dropdown in δ 65Cu ± 2 s.d. (‰) from − 0.40 ± 0.09 (pre-LTx) to − 
0.75 ± 0.14 (9 months post-LTx).
For a few patients (2, 29 and 32), the Cu isotopic composition remained very light, even more than one year 
post-LTx (Fig. 4). Patient 2, who underwent LTx because of alcoholic cirrhosis and HCC, was an outlier (Fig. 1), 
showing a serum δ 65Cu ± 2 s.d. value 9 months post-LTx of − 1.26 ± 0.12‰. This patient was monitored up to 3 
years post-LTx (Fig. 4d) and at this date, the δ 65Cu value had further dropped to − 1.73 ± 0.03 (2 s.d.)‰. On the 
basis of the clinical information, this patient seemed to have recovered well from the LTx without complications, 
recurrent liver disease, and other chronic or genetic disorders. Until now, no clear explanation can be given for 
these very negative δ 65Cu values.
Liver Pre-LTx 3 months post-LTx
p-value Normal rangeparameter Median s.d. Range (min–max) Median s.d. Range (min–max)
Bilirubin (mg dL−1) 3.0 9.8 0.3–46.6 0.60 0.86 0.2–4.1 0.000 0.2–1.1
Alb (g L−1) 34.0 7.8 22–49 37.0 8.4 19–44 > 0.05 34–48
AST (U L−1) 48 36 19–153 25 35 8–169 0.001 0–37
ALT (U L−1) 31 39 8–182 23 56 6–283 > 0.05 7–40
PT (%) 60 25 21–117 88 14 54–114 0.000 70–120
INR 1.43 0.72 0.9–3.7 1.10 0.12 0.9–1.5 0.000 0.9–1.1
Table 2.  Liver function parameters (bilirubin, Alb, AST, ALT, PT and INR) pre-LTx and 3 months 
post-LTx. The median, standard deviation and range (minimum value and maximum value observed) are 
represented for each cohort (pre-LTx and post-LTx). A significant change, i.e. normalization, in bilirubin, AST, 
PT and INR was observed 3 months post-LTX (p < 0.01, related samples Wilcoxon signed rank test). For clarity, 
also the normal ranges of these liver function parameters are shown.
Figure 3. Follow-up of serum δ65Cu values in patients without recurrence of liver failure. Error bars 
represent 2 s.d. The grey area represents the reference range (average value ± 1 s.d.) for healthy individuals24. 
Patients follow a gradual increase in δ 65Cu post-LTx. (a) Patients 17 and 22 (b) Patients 9 and 20. (c) Patients 12 
and 24. (d) Patient 5.
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Patient 29 (Fig. 4b) underwent transplantation due to hepatitis C virus cirrhosis (HCV C) and was re-transplanted 
14 days after the first LTx due to primary non-function. Although the patient recovered completely afterwards, 
he showed a very prolonged post-operative status with slow recuperation of liver function (Supplementary Table 
S1). This possibly contributed to the decline in the δ 65Cu ± 2 s.d. value from − 0.50 ± 0.11‰ (before the first LTx) 
to − 0.78 ± 0.03‰ (9 months after the first LTx). In this case, δ 65Cu value could potentially also have reached the 
range of healthy individuals at a later time, but unfortunately, no such serum samples were available.
Four patients passed away during the course of this work (8, 16, 18 and 31) and they all showed abnor-
mal trends and/or light Cu isotopic composition, probably related with additional complications and diseases 
post-LTx. Patients 8 and 16 died at 3 months post-LTx. Patient 8 presented acute renal failure, but the trans-
planted liver was functioning properly, which is likely the reason of the change in serum δ 65Cu towards the 
reference value. Patient 16 deceased due to sepsis and hepatorenal syndrome, which might explain the slight 
decrease in serum δ 65Cu following LTx. Patient 18 was diagnosed with recurrence of liver failure 10 months 
post-LTX and died 23 months post-LTx. However, 3 months post-LTx, no liver disorders were established and the 
serum δ 65Cu values had increased within the first months post-LTx. For patient 31 (Fig. 5), who was diagnosed 
with HCV C and HCC, the δ 65Cu ± 2 s.d. value pre-LTx (− 0.49 ± 0.02‰), approximated the reference range 
and remained more or less stable within 9 months post-LTx. However, at 12 months post-LTx, the δ 65Cu value 
declined very strongly to − 0.96 ± 0.03 (2 s.d.)‰ and at 15 months post-LTx, the patient was diagnosed with 
recurrent lung-metastasized HCC. Since this tremendous change in δ 65Cu was observed 3 months before the 
diagnosis of lung-metastasized HCC, this case seems to illustrate the added value of the Cu isotopic composition 
in blood serum as an additional parameter to assess presence/recurrence of liver disease.
Figure 4. Particular trends observed in serum δ65Cu values post-LTx. Error bars represent 2 s.d. The grey 
area represents the reference range (average value ± 1 s.d.) for healthy individuals24. (a) Patient 23. (b) Patient 
29. (c) Patient 32. (d) Patient 2.
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Discussion
Patients with ESLD showed a significantly lighter serum Cu isotopic composition (by about − 0.50‰) than the 
reference population, in concordance with the fractionation observed previously for another liver cirrhosis 
patient cohort studied (also by about − 0.50‰)19. This enrichment in the light Cu isotope was higher in serum 
from ESLD patients than that reported for HCC patients20. However, the wide spread in the δ 65Cu values in both 
ESLD and HCC could reflect the heterogeneity of the patient´s condition, e.g., severity of the disease. Even more, 
some patients had developed HCC and liver biopsies of HCC patients revealed that tumors are systematically 
65Cu-enriched relative to normal adjacent tissue (by about − 0.50‰)20, which can enhance the 65Cu depletion 
observed in serum.
Natural variations in the isotopic composition of transition metals in organisms are attributed to differences 
in coordination environments and in oxidation state. Heavier isotopes favour hard bonds, i.e. bonds to amino 
acids with harder ligands (binding to N or O), while lighter isotopes form preferentially bonds to softer ligands 
(binding to S)24. In serum, Cu is mostly bound to Cp and to a lesser extent to transcuprein, Alb and some low 
molecular weight components26. Since the liver is the major source of most serum proteins, liver disease affects 
Cp and Alb synthesis, function and redox change, and therefore Cu-binding27,28. Patients with cirrhosis typically 
have lower Alb and higher Cp levels22. In the liver, Cu and Zn are bound with strong affinity to metallothionein 
(MT), a cysteine-rich protein which converts these elements into a non-toxic form and acts as chaperone for 
providing Cu and Zn to several metalloenzymes29. Increased hepatic and plasma MT levels have been reported in 
liver disease associated with increased liver Cu concentration, such as cholestasis. Obstruction of bile flow results 
in the re-absorption of the cuproproteins from the bile and retention of Cu in the hepatocytes6,7. Elevated MT 
concentrations may be related to detoxification of hepatic accumulated copper, which can possibly explain the 
normal plasma MT concentrations found in liver disease, not accompanied by an elevated hepatic Cu concen-
tration30,31. Alterations in these proteins can induce the Cu isotope fractionation observed in serum. It has been 
suggested that low δ 65Cu values in serum of HCC patients are related with the release of intracellular Cu from 
cysteine clusters in MT20.
The potential of the serum Cu isotopic composition for diagnosis, management of liver disease and prioritiza-
tion of liver transplants was previously pointed out19. Monitoring of ESLD patients post-LTx revealed an increase 
in the serum δ 65Cu value, tending to the reference value, i.e. normalization, when the patient recovers normal 
liver function. The fluctuations or slight decreases in the δ 65Cu values observed in a minority of this cohort, espe-
cially at 3 months post-LTx, can be related with abnormal liver function or slow recuperation. A strong dropdown 
in δ 65Cu values at long-term post-LTx (e.g., 9 months) can be indicative of a life-threatening condition (Fig. 5). 
Thus, the serum Cu isotopic composition seems to predict the recurrence of HCC and/or liver failure.
In general, WD patients improve Cu metabolism32 and patients with cholestasis have progressive increase in 
biliary Cu secretion rates and lower levels of urinary Cu after LTx. A disturbance in Cu metabolism and biliary 
secretion has been observed in the immediate postoperative period, which was restored during the next weeks33. 
A series of surgeries on biliary artresia patients have shown a decrease in hepatic Cu content with the improve-
ment of cholestasis after the establishment of bile excretion34. Plasma Alb increased markedly post-LTx and nor-
mal or near-to-normal liver function parameters, such as PT, serum bilirubin, AST and ALT, were observed in 
liver-transplant patients35. Even more, it has been shown that products of hepatic synthesis permanently retain 
the metabolic specificity of the donor36. Thus, a general normalization in the Cu isotopic composition following 
LTx can be the evidence of the restored hepatic biosynthetic capacity, e.g., a normalization in Cp and Alb synthe-
sis, to a restored hepatic metabolism and/or to restored biliary secretion pathways.
In our previous work on liver cirrhosis patients, it was already suggested that δ 65Cu in serum could be used for 
the diagnosis and prognosis of liver cirrhosis19. The δ 65Cu values were significantly correlated with bilirubin, AST, 
Figure 5. Trend in serum δ65Cu value in a deceased patient with HCC. Error bars represent 2 s.d. A 
tremendous decrease in δ 65Cu can be observed at 12 months post-LTx. The patient was diagnosed with 
recurrence of lung-metastasized HCC 15 months post-LTx and deceased 3 months later.
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PT, INR and Alb. Even more, a significant correlation between δ 65Cu and the model for end-stage liver disease 
(MELD) score was found. This exploratory study suggests that Cu isotopic analysis in blood serum could also be 
a valuable non-invasive tool for the long-term monitoring of a patient’s liver function after LTx and for assessing 
recurrence of liver disease and HCC.
Methods
Samples. Serum samples of 32 patients (28 male and 4 female; age range, 28–70 years) who underwent LTx, 
were acquired from the Ghent University Hospital (UZGent, Belgium). Blood serum samples were collected 
within the week or month (two patients) pre-LTx and approximately 3 months post-LTx to evaluate the Cu iso-
topic signature. For a longer-term follow-up, samples taken up to ≥ 1 year post-LTx were included for some 
patients. In total, about 100 blood serum samples were analyzed.
Each blood sample was originally collected in a BC Vacutainer blood tube, suitable for trace element analysis 
and subsequently centrifuged. After centrifugation, the serum samples were analysed at the Ghent University 
Hospital for determination of various clinical parameters. An aliquot of about 500 μ L of serum sample was trans-
ferred to a pre-cleaned Eppendorf tube and stored at − 20 °C until sample preparation commenced.
Sample Preparation. An aliquot of about 500 μ L of blood serum was digested using 2 mL of 14 M 
sub-boiled pro-analysis HNO3 and 0.5 mL of 9.8 M ultra-pure H2O2 in Teflon Savillex® beakers at 110 °C for 18h. 
Subsequently, the sample digests were evaporated to dryness at 90 °C and redissolved in 5 mL of (8 M Optima 
grade HCl + 0.001% H2O2). Chemical purification of the samples was achieved via a modification of the sepa-
ration protocol37,38 using AG-MP1 anion exchange resin. For this, Bio-Rad Poly-Prep® columns were filled with 
1 mL of AG-MP1 resin. The resin was cleaned with 2 mL of 7 M HNO3 and 5 mL of 0.7 M HNO3, each time 
followed by rinsing with ~5 mL of Milli-Q H2O and it was subsequently conditioned with 5 mL of (8 M HCl + 
0.001% H2O2). After sample loading, the matrix was removed using 3 mL of (8 M HCl + 0.001% H2O2), followed 
by the elution of Cu using 9 mL of (5 M HCl + 0.001% H2O2) and the removal of Fe and Zn using 0.6 M HCl and 
0.7 M HNO3, respectively. The Cu-fraction collected was evaporated to dryness at 90 °C, redissolved in 5 mL of 
(8 M HCl + 0.001% H2O2) and subjected to a second isolation on the same column using the same procedure. 
After this second isolation, the Cu-fraction was evaporated to dryness at 90 °C and redissolved in 1 mL of 14 M 
HNO3. This step was performed twice. The final residue was redissolved in 500 μ L of 0.42 M HNO3.
In each batch of samples, blanks, a 1000 μ g L−1 Cu in-house standard solution (Inorganic Ventures, lot 
C2-Cu02116) and the SeronormTM Trace Element Sero L-1 (SERO AS, lot 0903106) were included and treated in 
the same way.
The complete sample preparation procedure, including digestion, chemical purification and dilutions, was 
carried out in a class 10 clean room.
Instrumentation and measurement protocols. Cu isotope ratio measurements were accomplished 
using a Neptune MC-ICP-MS instrument (Thermo Scientific, Germany), equipped with the Jet interface (X-type 
Ni skimmer and Jet type Ni sampler) for enhancing the sensitivity. The samples were introduced using a 100 μ L 
min−1 PFA nebulizer and a dual spray chamber, consisting of a cyclonic and a Scott-type sub-unit. Measurements 
were performed using five Faraday collectors (connected to 1011 Ω amplifiers) in static mode. The instrument set-
tings and data acquisition parameters are included in Supplementary Table S3. All measurements were performed 
at a mass position located 0.037 amu left from the center of the spectral peak plateau to avoid any effect of spectral 
interference present in the matrix.
Cu concentrations in the sample and isotopic standard solutions were adjusted to 200 μ g L−1 and for some 
samples with low Cu levels to 100 μ g L−1 Cu. For mass bias correction, the solutions were doped with Ni as inter-
nal standard. All samples and standards were measured following a sample-standard bracketing sequence. An 
in-house isotopic Cu standard previously characterized isotopically was included every 5 samples for checking 
the quality of the measurements.
Cu isotope ratios were determined off-line after 2 s.d. rejection of outliers. Correction for mass discrimination 
was performed using a combination of external correction in a sample-standard bracketing (SSB) approach and 
internal correction (with Ni) by means of the revised Russell’s law as described by Baxter et al.39. The isotopic 
composition of Cu is expressed in delta notation (per mil, ‰), calculated against the NIST SRM 976 Cu isotopic 
reference material using equation (1):
δ =



−



×Cu
( Cu/ Cu)
( Cu/ Cu)
1 1000
(1)
65
65 63
sample
65 63
NIST SRM 976
Elemental analysis was carried out using an Element XR sector field ICP-MS (SF-ICP-MS) instrument 
(Thermo Scientific, Germany) equipped with Ni cones (1.1 and 0.8 mm aperture diameter for the sampler and 
skimmer, respectively). Sample introduction was accomplished via a 200 μ L min−1 quartz concentric nebulizer 
and a cyclonic spray chamber. The instrumental settings and data acquisition parameters used are also sum-
marized in Supplementary Table S3. Levels of Cu and some elements that can give rise to spectral interference 
(Na and Mg) were determined both after digestion and after the isolation procedure. For quantitative elemental 
determination, external calibration was relied on with Ga as an internal standard.
Method Validation. Purification of biological samples is highly recommended to avoid matrix-induced mass 
bias and spectral interference40. For Cu isotopic analysis in serum, the major problem arises from the presence 
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of high levels of Na and, to a lesser extent Mg, leading to the occurrence of 40Ar23Na+ and 40Ar25Mg+, which can 
interfere with the monitoring of 63Cu+ and 65Cu+, respectively. For solutions containing 200 μ g L−1 of Cu of the 
in-house standard, 200 μ g L−1 of Ni and 1000 μ g L−1 of Na, the average δ 65Cu value, after mass bias correction 
according to Baxter’s method39, was 0.17 ± 0.03 (2 s.d.)‰ (n = 5). This value was in good agreement with the 
reference δ 65Cu value for the in-house standard, i.e. 0.22 ± 0.07 (2 s.d.)‰38. After 2 subsequent isolations, the Na/
Cu and Mg/Cu ratios (determined via SF-ICP-MS) observed in the Cu-fractions were always less than 1.5 and 1, 
respectively. Thus, no influence was observed on the Cu isotope ratio results under the conditions described.
Since chromatographic purification can induce on-column fractionation41, quantitative recovery is manda-
tory. For this reason, Cu levels were determined via SF-ICP-MS both after digestion and after isolation, yielding a 
Cu recovery of 95 ± 5% for all samples. The δ 65Cu ± 2 s.d. (‰) values for the SeronormTM Trace Elements Serum 
L-1 reference material and the in-house standard were − 0.24 ± 0.14 and 0.12 ± 0.13, respectively, both obtained 
after 4 different isolation and measurement sessions. The delta-value for the Cu in-house standard, measured 
every 5 samples, was always in good agreement with the expected value.
The procedural blanks were always measured at the beginning of each measurement session. As the bias 
between the results with and without blank correction was always less than 0.05‰, no blank correction was 
performed.
Statistical Analysis. All statistical tests were performed using the IBM® SPSS Statistics 23 software for 
Windows. The related samples Wilcoxon signed rank test – i.e. a non-parametric alternative for the paired sample 
t-test – was performed for establishing differences in Cu levels and Cu isotope ratios in serum of patients pre- and 
post-LTx. The threshold for significance was defined as α = 0.05.
Ethics Statement. This research project was approved by an independent commission for medical eth-
ics connected to the Ghent University Hospital and was performed in accordance with the guidelines for good 
clinical practice and the statement of Helsinki, emplaced to protect volunteers participating in experiments. All 
patients signed an informed consent form concerning this study.
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